These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29256624)

  • 1. Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement.
    Heltshe SL; Rowe SM; Skalland M; Baines A; Jain M;
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1483-1486. PubMed ID: 29256624
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.
    Magne F; Durupt S; Nove-Josserand R; Bey-Omar F; Laoust L; Cottin V; Durieu I; Reynaud Q
    J Cyst Fibros; 2017 Jan; 16(1):89-90. PubMed ID: 27810230
    [No Abstract]   [Full Text] [Related]  

  • 4. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
    Casciaro R; Costa S; Dang P; Majo F; Ros M
    Clin Respir J; 2018 Apr; 12(4):1767-1768. PubMed ID: 28759146
    [No Abstract]   [Full Text] [Related]  

  • 5. The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review.
    Dryden C; Wilkinson J; Young D; Brooker RJ;
    Arch Dis Child; 2018 Jan; 103(1):68-70. PubMed ID: 27288428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor.
    Chassagnon G; Hubert D; Fajac I; Burgel PR; Revel MP;
    Eur Respir J; 2016 Jul; 48(1):249-52. PubMed ID: 27230445
    [No Abstract]   [Full Text] [Related]  

  • 7. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
    McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
    Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Ivacaftor in Three Pediatric Siblings With Cystic Fibrosis Carrying the Mutations G551D And F508del.
    Mainz JG; Arnold C; Hentschel J; Tabori H
    Arch Bronconeumol (Engl Ed); 2018 Apr; 54(4):232-234. PubMed ID: 29103672
    [No Abstract]   [Full Text] [Related]  

  • 9. Time for a gut check: Pancreatic sufficiency resulting from CFTR modulator use.
    Megalaa R; Gopalareddy V; Champion E; Goralski JL
    Pediatr Pulmonol; 2019 Aug; 54(8):E16-E18. PubMed ID: 31066218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivacaftor and Airway Inflammation in Preschool Children with Cystic Fibrosis.
    McNally P; Butler D; Karpievitch YV; Linnane B; Ranganathan S; Stick SM; Hall GL; Schultz A
    Am J Respir Crit Care Med; 2021 Sep; 204(5):605-608. PubMed ID: 34077699
    [No Abstract]   [Full Text] [Related]  

  • 11. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
    Trimble AT; Donaldson SH
    J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiators for cystic fibrosis - targeting the underlying molecular defect.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Paediatr Respir Rev; 2015 Jun; 16(3):162-4. PubMed ID: 26002404
    [No Abstract]   [Full Text] [Related]  

  • 13. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating Specific Variants Causing Cystic Fibrosis.
    Cutting GR
    JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
    [No Abstract]   [Full Text] [Related]  

  • 15. Reduction of Recurrence Risk of Pancreatitis in Cystic Fibrosis With Ivacaftor: Case Series.
    Carrion A; Borowitz DS; Freedman SD; Siracusa CM; Goralski JL; Hadjiliadis D; Srinivasan S; Stokes DC
    J Pediatr Gastroenterol Nutr; 2018 Mar; 66(3):451-454. PubMed ID: 29045347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience.
    Dagan A; Cohen-Cymberknoh M; Shteinberg M; Levine H; Vilozni D; Bezalel Y; Bar Aluma BE; Sarouk I; Ashkenazi M; Lavie M; Tsabari R; Blau H; Kerem E; Bentur L; Efrati O; Livnat G
    Respir Med; 2017 Oct; 131():225-228. PubMed ID: 28947035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
    Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
    Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients.
    Gostelie R; Stegeman I; Berkers G; Bittermann J; Ligtenberg-van der Drift I; Kipshagen PV; de Winter-de Groot K; Speleman L
    PLoS One; 2020; 15(7):e0235638. PubMed ID: 32687499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial.
    Ratjen F; Klingel M; Black P; Powers MR; Grasemann H; Solomon M; Sagel SD; Donaldson SH; Rowe SM; Rosenfeld M
    Am J Respir Crit Care Med; 2018 Aug; 198(4):526-528. PubMed ID: 29614238
    [No Abstract]   [Full Text] [Related]  

  • 20. Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations.
    Stallings VA; Sainath N; Oberle M; Bertolaso C; Schall JI
    J Pediatr; 2018 Oct; 201():229-237.e4. PubMed ID: 30029855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.